Scope
This focused summary of WHO’s September 2026 malaria guideline covers clinical diagnosis, blood-stage treatment, relapse prevention, severe-malaria emergencies and selected prevention updates. It distinguishes falciparum transmission-blocking primaquine from vivax/ovale radical cure, and preserves the separate rules for pregnancy, small infants and G6PD deficiency. Global recommendations require national adaptation to resistance, formulations and local epidemiology.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Confirm infection and identify urgent disease
- Confirm suspected malaria with microscopy or a rapid diagnostic test supported by quality assurance. Reassess negative tests for other causes of fever; malaria symptoms alone are nonspecific. [1]
- Do not delay antimalarial treatment for suspected severe malaria because testing is unavailable or delayed. If an initial blood film is negative despite compatible severe illness, repeat films at 6–12-hour intervals or perform an appropriate rapid test while investigating alternative diagnoses. [1]
- Treat inability to take oral medicines reliably, vital-organ dysfunction or a high parasite count as warning signs requiring the highest available level of care. Suspected severe malaria requires immediate supportive care and parenteral treatment, without waiting to satisfy an epidemiological case definition. [1]
Choose effective blood-stage treatment
- For uncomplicated falciparum malaria, use an effective artemisinin-based combination therapy, with three days of the artemisinin component. Options include artemether–lumefantrine, artesunate–amodiaquine, artesunate–mefloquine, dihydroartemisinin–piperaquine, artesunate–sulfadoxine/pyrimethamine or artesunate–pyronaridine; local efficacy and patient safety determine selection. [1]
- For uncomplicated falciparum malaria in the first trimester, use artemether–lumefantrine. Artesunate–amodiaquine, artesunate–mefloquine or dihydroartemisinin–piperaquine may be considered if it is unavailable or unsuitable under national policy; sulfadoxine/pyrimethamine-containing ACTs are contraindicated, and artesunate–pyronaridine is not recommended in this trimester. [1]
- For infants below 5 kg with uncomplicated falciparum malaria, use the same target mg/kg ACT dose as for a 5-kg child. Where artemether–lumefantrine is available, use the newer infant formulation with a 1:12 ratio. [1]
- Avoid artesunate–pyronaridine in clinically apparent liver disease. In patients with HIV receiving co-trimoxazole, do not use artesunate–sulfadoxine/pyrimethamine; avoid artesunate–amodiaquine with efavirenz or zidovudine. [1]
- For uncomplicated malaria when the species is uncertain, treat as uncomplicated falciparum malaria. In chloroquine-susceptible settings, uncomplicated vivax, ovale, malariae or knowlesi infection may receive ACT or chloroquine; use ACT in chloroquine-resistant settings. [1]
Separate transmission reduction from relapse prevention
- In low-transmission settings, give single-dose primaquine 0.25 mg/kg with an ACT for falciparum malaria to reduce transmission; G6PD testing is not required for this specific regimen. Exclude pregnant women, infants younger than 1 month and women breastfeeding infants younger than 1 month. [1]
- Do not generalize single-low-dose primaquine to moderate- or high-transmission areas, including those with antimalarial resistance. WHO does not recommend that use because effectiveness in reducing transmission or resistant-parasite spread is unproven. [1]
- For vivax or ovale relapse prevention, use G6PD status to choose treatment. A qualitative test can identify activity below 30% but misses females with intermediate activity of 30–70%; a normal qualitative result does not establish eligibility for high-dose short-course primaquine or tafenoquine. [1]
- WHO recommends a higher total primaquine course for eligible vivax or ovale patients, but excludes pregnancy, infants younger than 1 month, breastfeeding an infant younger than 1 month and G6PD deficiency from that standard regimen. Lower total-dose treatment may remain appropriate on the Indian subcontinent where the additional benefit is smaller. [1]
- For G6PD deficiency, a supervised weekly primaquine regimen is a conditional option requiring close monitoring for haemolysis. If G6PD testing is unavailable, an individualized risk–benefit decision is required; the no-testing rule for single-dose falciparum transmission reduction must not be applied to radical cure. [1]
- Tafenoquine’s conditional vivax anti-relapse recommendation is restricted to South America, age at least 2 years, adequate measured G6PD activity and concurrent chloroquine. It is not recommended with ACT blood-stage treatment or during pregnancy or lactation; deployment elsewhere requires controlled use or further research. [1]
Treat severe malaria and arrange referral
- Treat severe malaria in adults and children, including all pregnancy trimesters and lactation, with IV or IM artesunate for at least 24 hours and until oral medicine is tolerated. Then complete a full three-day ACT course; early improvement does not justify omitting the minimum parenteral period. Avoid a mefloquine-containing ACT if the patient initially had impaired consciousness. [1]
- For severe malaria, children below 20 kg need artesunate 3 mg/kg per dose; larger children and adults receive 2.4 mg/kg per dose under the full parenteral schedule. If artesunate is unavailable, artemether is preferred to quinine. [1]
- If full severe-malaria care is unavailable, give a single IM artesunate dose and refer for completion; use IM artemether, then IM quinine, if earlier options are unavailable. Where IM artesunate cannot be given, children younger than 6 years may receive rectal artesunate 10 mg/kg once followed by immediate referral. Do not use rectal artesunate in older children or adults. [1]
Monitor complications and coexisting disease
- For severe malaria, secure airway, breathing and circulation and urgently measure glucose, haemoglobin or haematocrit, parasitaemia and adult renal function. Monitor vital signs, consciousness and urine output frequently; check glucose about every 4 hours where possible, especially if unconscious. [1]
- Individualize severe-malaria fluids and reassess frequently to avoid both underhydration and pulmonary oedema. Rapid crystalloid or colloid boluses are contraindicated in this guidance; do not automatically transfer generic fever-fluid algorithms to severe malaria. [1]
- Sepsis can coexist with malaria. In endemic areas, start empirical parenteral broad-spectrum antibiotics with antimalarial therapy for a shocked or severely ill obtunded child when septicaemia cannot promptly be excluded; obtain blood culture where possible. [1]
Use setting-specific prevention
- In malaria-endemic pregnancy, preventive treatment is distinct from treatment of symptomatic malaria. IPTp sulfadoxine/pyrimethamine begins in the second trimester, not before 13 weeks, with doses at least a month apart and a goal of at least three doses. It is contraindicated with co-trimoxazole prophylaxis in women with HIV. [1]
- Do not use dihydroartemisinin–piperaquine as intermittent preventive treatment for pregnant women with HIV in malaria-endemic settings. This newer conditional recommendation concerns prevention and must not be confused with ACT treatment selection for confirmed malaria. [1]
- WHO recommends malaria vaccination for children in endemic areas, prioritizing moderate- and high-transmission settings. Standard delivery uses four doses from around 5 months, adapted by national programmes. Vaccination provides partial protection and complements other preventive measures rather than replacing them. [1]
Limitations and use
- This is selected clinical guidance, not the complete global programme manual. Vector control, mass drug administration, elimination, resistance surveillance, travel prophylaxis and full recurrent-infection pathways are not reproduced.
- ACT weight-band prescriptions, complete injectable artesunate timing, antimalarial preparation instructions, transfusion thresholds and full organ-support protocols are outside this summary. Refer to the complete regimen and locally effective treatment policy; a per-dose amount is not a complete schedule.
- Radical-cure dose selection requires validated G6PD testing, pregnancy/lactation assessment, geographic relapse risk and monitoring. The source uses differing greater-than versus at-least wording around the high-activity G6PD boundary; this summary does not turn that boundary into an independent prescribing algorithm or present tafenoquine as routine Indian treatment.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- WHO guidelines for malaria
Selected recommendation material consulted
Publication details
- Issuing organisation
- WHO
- First published
- 10 September 2026
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.